VBI Vaccines Inc. [NASDAQ: VBIV] closed the trading session at $2.87 on 04/08/21. The day’s price range saw the stock hit a low of $2.80, while the highest price level was $2.95. The company report on March 15, 2021 that VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference.
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17 at 10:40 AM ET.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
The stocks have a year to date performance of 4.36 percent and weekly performance of -7.72 percent. The stock has been moved at 1.41 percent over the last six months. The stock has performed -8.89 percent around the most recent 30 days and changed -4.33 percent over the most recent 3-months.
If compared to the average trading volume of 7.02M shares, VBIV reached to a volume of 3561988 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about VBI Vaccines Inc. [VBIV]:
Jefferies have made an estimate for VBI Vaccines Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 25, 2021. While these analysts kept the previous recommendation, Raymond James raised their target price from $8 to $9. The new note on the price target was released on August 27, 2020, representing the official price target for VBI Vaccines Inc. stock. Previously, the target price had yet another raise to $9, while Oppenheimer analysts kept a Outperform rating on VBIV stock.
The Average True Range (ATR) for VBI Vaccines Inc. is set at 0.23, with the Price to Sales ratio for VBIV stock in the period of the last 12 months amounting to 660.65. The Price to Book ratio for the last quarter was 4.04, with the Price to Cash per share for the same quarter was set at 0.47.
VBIV stock trade performance evaluation
VBI Vaccines Inc. [VBIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.72. With this latest performance, VBIV shares dropped by -8.89% in over the last four-week period, additionally plugging by 1.41% over the last 6 months – not to mention a rise of 206.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBIV stock in for the last two-week period is set at 38.99, with the RSI for the last a single of trading hit 35.28, and the three-weeks RSI is set at 41.73 for VBI Vaccines Inc. [VBIV]. The present Moving Average for the last 50 days of trading for this stock 3.42, while it was recorded at 2.98 for the last single week of trading, and 3.34 for the last 200 days.
VBI Vaccines Inc. [VBIV]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and VBI Vaccines Inc. [VBIV] shares currently have an operating margin of -4110.93 and a Gross Margin at -919.79. VBI Vaccines Inc.’s Net Margin is presently recorded at -4357.21.
Return on Total Capital for VBIV is now -29.66, given the latest momentum, and Return on Invested Capital for the company is -33.29. Return on Equity for this stock declined to -35.57, with Return on Assets sitting at -27.89. When it comes to the capital structure of this company, VBI Vaccines Inc. [VBIV] has a Total Debt to Total Equity ratio set at 10.42. Additionally, VBIV Total Debt to Total Capital is recorded at 9.44, with Total Debt to Total Assets ending up at 8.55. Long-Term Debt to Equity for the company is recorded at 9.87, with the Long-Term Debt to Total Capital now at 8.94.
Reflecting on the efficiency of the workforce at the company, VBI Vaccines Inc. [VBIV] managed to generate an average of -$364,016 per employee. Receivables Turnover for the company is 0.26 with a Total Asset Turnover recorded at a value of 0.01.VBI Vaccines Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.50 and a Current Ratio set at 7.60.
VBI Vaccines Inc. [VBIV]: Insider Ownership positions
There are presently around $349 million, or 53.20% of VBIV stock, in the hands of institutional investors. The top three institutional holders of VBIV stocks are: PERCEPTIVE ADVISORS LLC with ownership of 55,042,465, which is approximately 0% of the company’s market cap and around 3.28% of the total institutional ownership; STATE STREET CORP, holding 22,293,634 shares of the stock with an approximate value of $63.98 million in VBIV stocks shares; and BLACKROCK INC., currently with $37.81 million in VBIV stock with ownership of nearly 7.76% of the company’s market capitalization.
Positions in VBI Vaccines Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 82 institutional holders increased their position in VBI Vaccines Inc. [NASDAQ:VBIV] by around 11,449,446 shares. Additionally, 49 investors decreased positions by around 16,143,021 shares, while 14 investors held positions by with 93,947,228 shares. The mentioned changes placed institutional holdings at 121,539,695 shares, according to the latest SEC report filing. VBIV stock had 34 new institutional investments in for a total of 3,443,009 shares, while 23 institutional investors sold positions of 13,399,523 shares during the same period.